Impact of probiotic supplementation on trimethylamine N-oxide (TMAO) in humans: A systematic review and meta-analysis of randomized controlled trials

Sohouli, Mohammad Hassan; Ozovanu, Oana Deliu; Fatahi, Somaye; Hekmatdoost, Azita

doi:10.1016/j.clnesp.2022.06.006

Cited by 4 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dietary patterns and foods could also contribute to the observed differences. Namely, consuming different nutrients such as polyphenols or omega‐3 polyunsaturated fatty acid supplements could elevate circulating BDNF concentrations 96,97 . Thus, dietary habits of participants should be recorded when analyzing BDNF levels.…”

Section: Discussionmentioning

confidence: 99%

The association between levels of brain‐derived neurotrophic factor and comorbid depression in patients with cardiovascular disease: The Framingham Heart Study

Medved,

Salinas,

Kojis

et al. 2024

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

AimThe current study aims to investigate the association of serum brain‐derived neurotrophic factor (BDNF) levels with symptoms of depression in adults with and without prevalent cardiovascular disease (CVD), an often burdensome comorbidity.MethodsThis cross‐sectional study included participants from FHS (Framingham Heart Study) who had available serum BDNF levels. Depressive symptoms were assessed using the Center for Epidemiological Studies–Depression Scale (CES‐D) with a score ≥16 indicating mild to moderate and ≥21 severe depression. Participants taking antidepressant medications were excluded from the study.ResultsAltogether 3716 FHS participants were included in the final analysis (mean age, 64.3 ± 11.5 years; 55% women). After adjusting for potential confounders, greater BDNF levels were associated with reduced severe depression risk (odds ratio [OR], 0.78 [95% CI, 0.64–0.96]; P = 0.016). Among participants with CVD, greater BDNF levels were related to lower risk of depressive symptoms (CES‐D ≥ 16 OR, 0.63 [95% CI, 0.45–0.89], P = 0.008; CES‐D ≥ 21 OR, 0.49 [95% CI, 0.31–0.76], P = 0.002). The inverse relationship between BDNF and depressive symptom risk was present in women with CVD (CES‐D ≥ 16 OR, 0.63 [95% CI, 0.40–0.99], P = 0.047; CES‐D ≥ 21 OR, 0.38 [95% CI, 0.21–0.70], P = 0.002) but not in men.ConclusionLower serum BDNF levels are associated with a higher risk of depressive symptoms in CVD, particularly among women. These findings implicate BDNF in the complex biological mechanisms that underlie prior associations observed between CVD and depression. To reduce the burden of depression in the large proportion of midlife and older adults with CVD, a better understanding of how BDNF may modify these pathways is merited.

show abstract

Section: Discussionmentioning

confidence: 99%

The association between levels of brain‐derived neurotrophic factor and comorbid depression in patients with cardiovascular disease: The Framingham Heart Study

Medved,

Salinas,

Kojis

et al. 2024

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

show abstract

Human Gut Microbiota in Cardiovascular Disease

Ronen,

Rokach,

Abedat

et al. 2024

Comprehensive Physiology

View full text Add to dashboard Cite

The gut ecosystem, termed microbiota, is composed of bacteria, archaea, viruses, protozoa, and fungi and is estimated to outnumber human cells. Microbiota can affect the host by multiple mechanisms, including the synthesis of metabolites and toxins, modulating inflammation and interaction with other organisms. Advances in understanding commensal organisms' effect on human conditions have also elucidated the importance of this community for cardiovascular disease (CVD). This effect is driven by both direct CV effects and conditions known to increase CV risk, such as obesity, diabetes mellitus (DM), hypertension, and renal and liver diseases. Cardioactive metabolites, such as trimethylamine N ‐oxide (TMAO), short‐chain fatty acids (SCFA), lipopolysaccharides, bile acids, and uremic toxins, can affect atherosclerosis, platelet activation, and inflammation, resulting in increased CV incidence. Interestingly, this interaction is bidirectional with microbiota affected by multiple host conditions including diet, bile acid secretion, and multiple diseases affecting the gut barrier. This interdependence makes manipulating microbiota an attractive option to reduce CV risk. Indeed, evolving data suggest that the benefits observed from low red meat and Mediterranean diet consumption can be explained, at least partially, by the changes that these diets may have on the gut microbiota. In this article, we depict the current epidemiological and mechanistic understanding of the role of microbiota and CVD. Finally, we discuss the potential therapeutic approaches aimed at manipulating gut microbiota to improve CV outcomes. © 2024 American Physiological Society. Compr Physiol 14:5449‐5490, 2024.

show abstract

The Gut Microbiome Affects Atherosclerosis by Regulating Reverse Cholesterol Transport

Jiang,

Pang,

Liu

et al. 2024

J. of Cardiovasc. Trans. Res.

View full text Add to dashboard Cite

Impact of probiotic supplementation on trimethylamine N-oxide (TMAO) in humans: A systematic review and meta-analysis of randomized controlled trials

Cited by 4 publications

References 41 publications

The association between levels of brain‐derived neurotrophic factor and comorbid depression in patients with cardiovascular disease: The Framingham Heart Study

The association between levels of brain‐derived neurotrophic factor and comorbid depression in patients with cardiovascular disease: The Framingham Heart Study

Human Gut Microbiota in Cardiovascular Disease

The Gut Microbiome Affects Atherosclerosis by Regulating Reverse Cholesterol Transport

Contact Info

Product

Resources

About